Brain cancer breakthrough? new CAR-NK cell trial targets glioblastoma

NCT ID NCT07480941

Recruiting now Disease control Sponsor: Beijing Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new approach for people with recurrent glioblastoma, a fast-growing brain tumor. Doctors take immune cells called NK cells, engineer them to recognize and attack tumor cells, and deliver them directly into the brain. The study will check safety and find the best dose in 36 adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR-NK cells (immune cells engineered to attack brain tumor cells)
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with very few effective therapies.
What could go wrong: This is a very early Phase 1 trial with only 36 participants, so safety and effectiveness are not yet proven. The treatment involves brain surgery and chemotherapy, which carry serious risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA HIGH GRADE GLIOMA MALIGNANT GLIOMA RECURRENT GLIOBLASTOMA RECURRENT HIGH GRADE GLIOMA

Contacts and locations

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.